We speak with Richard Hullihen, CEO of Polarean, following the successful enrolment of the first patient into the Phase III clinical trial which aims to demonstrate non-inferiority of the Company's drug/device combination
We speak with Richard Hullihen, CEO of Polarean, following the successful enrolment of the first patient into the Phase III clinical trial which aims to demonstrate non-inferiority of the Company's drug/device combination